CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
alirocumab appears in hypotheses across 3 disease domains: Alzheimer, Inflammatory bowel disease, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: PCSK9.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for alirocumab
Alzheimer 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| PCSK9 | Aβ accumulation | 0.248 | Mid | novel signal | none | |
| PCSK9 | Alzheimer's disease | 0.248 | Mid | partial evidence | none |
Inflammatory bowel disease 4
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| PCSK9 | endoscopic Mayo Score | 0.208 | Mid | novel signal | none | |
| PCSK9 | UC-Riley Index | 0.208 | Mid | novel signal | none | |
| PCSK9 | disease severity | 0.208 | Mid | novel signal | preclinical only | |
| PCSK9 | active ulcerative colitis | 0.208 | Mid | novel signal | none |
Rheumatoid arthritis 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| PCSK9 | atrial structural remodeling | 0.208 | Mid | novel signal | none | |
| PCSK9 | atrial fibrillation | 0.208 | Mid | partial evidence | none |